Seneca Biopharma completes cell manufacturing facility in Suzhou, China

Seneca Biopharma (formerly Neuralstem), a biopharma company engaged in developing treatments for diseases of high unmet medical need, has completed construction on its new cell manufacturing facility in Suzhou, China.

The cell manufacturing facility will be used  for manufacture NSI-566, the lead stem cell therapy of Seneca Biopharma for clinical trials in China, which includes a non-GCP compliant phase 2 trial, which is currently in progress for the treatment of chronic ischemic stroke at the BaYi Brain Hospital in Beijing.

Dr. Ken Carter – Executive Chairman of Seneca Biopharma said: “Completion of our new facility in Suzhou is a key milestone in Seneca’s product development strategy.

“This facility will allow us to manufacture cells to support our current and future clinical trials in China.” Further, Dr. Carter commented “I’d like to personally thank the staff who have been able to move forward on this plan while maintaining their safety during these uncertain times.”

Image courtesy of doodlartdotcom from Pixabay.

Related posts

• G42 Healthcare begins phase 3 trial of Sinopharm COVID-19 inactivated vaccine candidate in UAE (0)
• Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer (0)
• Sinovac Biotech gets approval for CoronaVac phase 3 trial in Brazil (0)
• BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS (0)
• China’s CF PharmTech raises $50m in Series F round for inhalation products (0)
• Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial (0)
• Sinovac Biotech CoronaVac COVID-19 vaccine candidate succeeds in phase 1/2 trial (0)
• Citius seeks FDA nod for evaluating stem cell therapy for ARDS in COVID-19 (0)
• COVID-19 RT-PCR detection kit : Fosun Pharma secures FDA EUA status (0)
• SARS-CoV-2 vaccine trial : Sinovac Biotec begins COVID-19 vaccine candidate human trial (0)